Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities

Z. Novakova, J. Cerny, CJ. Choy, JR. Nedrow, JK. Choi, J. Lubkowski, CE. Berkman, C. Barinka,

. 2016 ; 283 (1) : 130-43. [pub] 20151105

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK Free Medical Journals from 2005 to 1 year ago
Medline Complete (EBSCOhost) from 2005-01-01 to 1 year ago
Wiley Free Content from 2005 to 1 year ago

UNLABELLED: Inhibitors targeting human glutamate carboxypeptidase II (GCPII) typically consist of a P1' glutamate-derived binding module, which warrants the high affinity and specificity, linked to an effector function that is positioned within the entrance funnel of the enzyme. Here we present a comprehensive structural and computational study aimed at dissecting the importance of the effector function for GCPII binding and affinity. To this end we determined crystal structures of human GCPII in complex with a series of phosphoramidate-based inhibitors harboring effector functions of diverse physicochemical characteristics. Our data show that higher binding affinities of phosphoramidates, compared to matching phosphonates, are linked to the presence of additional hydrogen bonds between Glu424 and Gly518 of the enzyme and the amide group of the phosphoramidate. While the positioning of the P1' glutamate-derived module within the S1' pocket of GCPII is invariant, interaction interfaces between effector functions and residues lining the entrance funnel are highly varied, with the positively charged arginine patch defined by Arg463, Arg534 and Arg536 being the only 'hot-spot' common to several studied complexes. This variability stems in part from the fact that the effector/GCPII interfaces generally encompass isolated areas of nonpolar residues within the entrance funnel and resulting van der Waals contacts lack the directionality typical for hydrogen bonding interactions. The presented data unravel a complexity of binding modes of inhibitors within non-prime site(s) of GCPII and can be exploited for the design of novel GCPII-specific compounds. PDB ID CODES: Atomic coordinates of the present structures together with the experimental structure factor amplitudes were deposited at the RCSB Protein Data Bank under accession codes 4P44 (complex with JRB-4-81), 4P45 (complex with JRB-4-73), 4P4B (complex with CTT54), 4P4D (complex with MP1C), 4P4E (complex with MP1D), 4P4F (complex with NC-2-40), 4P4I (complex with T33) and 4P4J (complex with T33D).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020222
003      
CZ-PrNML
005      
20160805120617.0
007      
ta
008      
160722s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/febs.13557 $2 doi
024    7_
$a 10.1111/febs.13557 $2 doi
035    __
$a (PubMed)26460595
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Novakova, Zora $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
245    10
$a Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities / $c Z. Novakova, J. Cerny, CJ. Choy, JR. Nedrow, JK. Choi, J. Lubkowski, CE. Berkman, C. Barinka,
520    9_
$a UNLABELLED: Inhibitors targeting human glutamate carboxypeptidase II (GCPII) typically consist of a P1' glutamate-derived binding module, which warrants the high affinity and specificity, linked to an effector function that is positioned within the entrance funnel of the enzyme. Here we present a comprehensive structural and computational study aimed at dissecting the importance of the effector function for GCPII binding and affinity. To this end we determined crystal structures of human GCPII in complex with a series of phosphoramidate-based inhibitors harboring effector functions of diverse physicochemical characteristics. Our data show that higher binding affinities of phosphoramidates, compared to matching phosphonates, are linked to the presence of additional hydrogen bonds between Glu424 and Gly518 of the enzyme and the amide group of the phosphoramidate. While the positioning of the P1' glutamate-derived module within the S1' pocket of GCPII is invariant, interaction interfaces between effector functions and residues lining the entrance funnel are highly varied, with the positively charged arginine patch defined by Arg463, Arg534 and Arg536 being the only 'hot-spot' common to several studied complexes. This variability stems in part from the fact that the effector/GCPII interfaces generally encompass isolated areas of nonpolar residues within the entrance funnel and resulting van der Waals contacts lack the directionality typical for hydrogen bonding interactions. The presented data unravel a complexity of binding modes of inhibitors within non-prime site(s) of GCPII and can be exploited for the design of novel GCPII-specific compounds. PDB ID CODES: Atomic coordinates of the present structures together with the experimental structure factor amplitudes were deposited at the RCSB Protein Data Bank under accession codes 4P44 (complex with JRB-4-81), 4P45 (complex with JRB-4-73), 4P4B (complex with CTT54), 4P4D (complex with MP1C), 4P4E (complex with MP1D), 4P4F (complex with NC-2-40), 4P4I (complex with T33) and 4P4J (complex with T33D).
650    _2
$a amidy $x chemická syntéza $x chemie $x farmakologie $7 D000577
650    _2
$a antigeny povrchové $x metabolismus $7 D000954
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    12
$a racionální návrh léčiv $7 D015195
650    _2
$a inhibitory enzymů $x chemická syntéza $x chemie $x farmakologie $7 D004791
650    _2
$a glutamátkarboxypeptidasa II $x antagonisté a inhibitory $x metabolismus $7 D043425
650    _2
$a lidé $7 D006801
650    _2
$a vodíková vazba $7 D006860
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární struktura $7 D015394
650    _2
$a kyseliny fosforečné $x chemická syntéza $x chemie $x farmakologie $7 D010756
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cerny, Jiri $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Choy, Cindy J $u Department of Chemistry, Washington State University, Pullman, WA, USA.
700    1_
$a Nedrow, Jessie R $u Department of Chemistry, Washington State University, Pullman, WA, USA.
700    1_
$a Choi, Joeseph K $u Department of Chemistry, Washington State University, Pullman, WA, USA.
700    1_
$a Lubkowski, Jacek $u National Cancer Institute, Center for Cancer Research, Macromolecular Crystallography Laboratory, Frederick, MD, USA.
700    1_
$a Berkman, Clifford E $u Department of Chemistry, Washington State University, Pullman, WA, USA.
700    1_
$a Barinka, Cyril $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
773    0_
$w MED00008414 $t The FEBS journal $x 1742-4658 $g Roč. 283, č. 1 (2016), s. 130-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26460595 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160805120849 $b ABA008
999    __
$a ok $b bmc $g 1154892 $s 944750
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 283 $c 1 $d 130-43 $e 20151105 $i 1742-4658 $m The FEBS journal $n FEBS J $x MED00008414
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...